TLK1 and posterior cortical atrophy: It highlights some of our groundbreaking research at LSU Health Shreveport on Tousled-like kinase 1 (TLK1) and the J54 drug test molecule that could be poised to revolutionize our therapeutic approach, offering hope for a brighter future in PCa treatment [1].